#United States #Anixa Biosciences #Breast Cancer #Clinical Trial #San Jose, California

Anixa Biosciences to Present Groundbreaking Trial Results

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company dedicated to combating cancer, is preparing to present its final results from a pivotal Phase 1 clinical trial of its novel breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium (SABCS). Scheduled for December 11, 2025, this presentation is a critical milestone for Anixa as it seeks to advance its transformative vaccine technology into Phase 2 trials.

The trial, conducted by the renowned Cleveland Clinic, highlighted the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine designed to revolutionize breast cancer treatment. Funded by a grant from the U.S. Department of Defense, the study represents a pioneering effort in the fight against one of the most prevalent forms of cancer.

Presentation Details

The presentation, titled "Final Results of a Phase I Trial of Alpha-lactalbumin (aLA) Vaccine for Breast Cancer," will be delivered by Dr. Justin Johnson, Program Manager at Cleveland Clinic and co-inventor of the vaccine technology. Attendees can expect a comprehensive overview of the findings, providing an insight into the detailed analyses conducted on blood and tissue samples collected throughout the trial.

Abstract Number: 765
Presentation Number: PS4-06-19
Time: Thursday, December 11, 2025, 500–630 PM CST

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed optimism about the trial's data, stating, "We are very encouraged by the data generated in this human clinical trial, which continues to exceed our expectations. This vaccine builds on decades of pioneering preclinical work led by the late Vincent Tuohy, Ph.D. and his team at Cleveland Clinic. His visionary research has brought us to this pivotal moment—one that has the potential to transform the future of breast cancer prevention and treatment."

Significance of the Research

The completion of this Phase 1 trial is not just an academic event; it is a potential turning point in breast cancer prevention and treatment approaches. With the extensive results prepared for submission to both the U.S. Department of Defense and the U.S. Food and Drug Administration (FDA), Anixa Biosciences is on the cusp of advancing its plans for Phase 2 trials, which are crucial for further validating the vaccine's efficacy and safety in a larger population.

The aLA breast cancer vaccine stands out in its ability to stimulate an immune response specifically targeting cancer cells, potentially allowing for earlier detection and prevention of breast cancer. This innovative approach could dramatically change the standard operating procedures regarding breast cancer screening and treatment, offering hope to millions of patients and their families worldwide.

About Anixa Biosciences, Inc.

Headquartered in San Jose, California, Anixa Biosciences concentrates on pioneering therapeutic solutions for cancer treatment and prevention. The company's strategy involves collaborating with elite research institutions such as the Cleveland Clinic, ensuring that they remain at the forefront of cancer therapeutic development. Anixa's portfolio also includes promising programs for ovarian cancer immunotherapy in partnership with Moffitt Cancer Center, focusing on novel cell therapy technologies.

For further information on Anixa Biosciences and its groundbreaking work, please visit Anixa's official website or follow them on platforms such as LinkedIn, X, Facebook, and YouTube.

Looking Ahead

The upcoming presentation at SABCS is anticipated to foster significant dialogue within the scientific community regarding breast cancer treatment advancements. As Anixa aims to finalize its data presentation, its innovative approach underscores a rising trend in cancer research: the importance of immunotherapy in modern medicine's battle against cancer.

In conclusion, Anixa Biosciences is poised to redefine the landscape of breast cancer prevention and treatment, marking a promising advance in medical science and offering hope to countless individuals fighting this disease.